- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
AMD-therapy developer plans to sell stock
Mississauga, Ontario-OccuLogix, an ophthalmic therapeutic company working on treatments for age-related macular degeneration (AMD), plans to hold an initial public offering of its stock.
Mississauga, Ontario-OccuLogix, an ophthalmic therapeutic company working on treatments for age-related macular degeneration (AMD), plans to hold an initial public offering of its stock.
The company, formerly Vascular Sciences, and TLC Vision, its major shareholder, said it would file a registration statement with the SEC. Copies of the prospectus will be available from Citigroup Global Markets Inc.
Founded in 1996, OccuLogix is working on a variety of innovative treatments for eye disease, including rheopheresis, a filtering process designed to slow the progression of dry AMD by removing certain compounds in the blood. The business is valued at a total $350 million to $560 million, or $5 to $8 per TLC share.
